| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Pathology and 2 Surgery, College of Medicine, University of Saskatchewan, and 3 Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
Requests for reprints: Rajendra K. Sharma, Department of Pathology, College of Medicine, University of Saskatchewan, and Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4. Phone: 306-966-7733; Fax: 306-655-2635. E-mail: rsharma{at}scf.sk.ca
Background: Calpains represent a well-conserved family of Ca2+-dependent proteolytic enzymes. Recently, the importance of calpain in the metastatic process has received great attention. To investigate whether m-calpain contributes to the pathogenesis of colorectal cancer, we investigated the expression of m-calpain and its inhibitors, calpastatin and high-molecular-weight calmodulin-binding protein (HMWCaMBP), in human colorectal surgical specimens. Methods: Fifty cases of colon carcinoma were evaluated for this study. Of 50 cases evaluated, we presented in this report six cases for m-calpain, calpastatin and HMWCaMBP protein expression by Western blot analyses was done in both normal and invasive tumor components of human samples. In addition, immunohistochemistry analysis was also carried out in all patients. Results: The activity and protein expression of m-calpain was significantly higher in colorectal adenocarcinoma than in normal colonic mucosa. This finding was corroborated by immunohistochemical studies that showed strong cytoplasmic staining in the colon tumors with m-calpain antibody. The decreased expression of these calpain inhibitors (calpastatin and HMWCaMBP) paralleled increased activity and expression of calpain in colorectal adenocarcinoma and the well-documented involvement of this Ca2+-dependent protease in colon tumor. Conclusion: Increased activity and moderate staining of m-calpain in polyps show the usage of this enzyme as a marker for the early detection of colorectal adenocarcinoma using immunologic approaches. These findings represent the first description of calpain overexpression in colorectal cancer. This has implications with regard to the design of chemotherapeutic drugs as well as in monitoring colorectal cancer in early stages of the metastatic process.
This article has been cited by other articles:
|
|
 |
|
  J. Leblond, F. Le Pessot, A. Hubert-Buron, C. Duclos, J. Vuichoud, M. Faure, D. Breuille, P. Dechelotte, and M. Coeffier Chemotherapy-Induced Mucositis Is Associated with Changes in Proteolytic Pathways Experimental Biology and Medicine, February 1, 2008; 233(2): 219 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Libertini, C. G. Tepper, V. Rodriguez, D. M. Asmuth, H.-J. Kung, and M. Mudryj Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence Cancer Res., October 1, 2007; 67(19): 9001 - 9005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Merten, J. Stitz, G. Braun, J. Medvedovska, K. Cichutek, and C. J. Buchholz Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein Nucleic Acids Res., March 15, 2006; 34(5): e41 - e41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Libertini, B. S. Robinson, N. K. Dhillon, D. Glick, M. George, S. Dandekar, J. P. Gregg, E. Sawai, and M. Mudryj Cyclin E Both Regulates and Is Regulated by Calpain 2, a Protease Associated with Metastatic Breast Cancer Phenotype Cancer Res., December 1, 2005; 65(23): 10700 - 10708. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
